Retatrutide phase 2: largest weight loss reported in any class to date

Phase 2 results for retatrutide — a GLP-1, GIP, and glucagon triple agonist — were published from a 48-week study in adults with obesity.

Doses ranged from 1 mg to 12 mg weekly versus placebo.

The highest dose produced mean weight loss of about 24%, with dose-dependent metabolic improvements.

Side effects were predominantly gastrointestinal and consistent with the GLP-1 class.

Phase 3 trials are underway with cardiovascular outcomes built in.

Approval, if granted, is likely still 18-24 months out.